Insulin Glargine biosimilar (Liaoning Bo'Ao Bio-Pharmaceutical)

甘精胰岛素生物类似药（辽宁博鳌生物制药）

Report date: 2023/12/11 09:28:04

Base Information

Drug NameInsulin Glargine biosimilar (Liaoning Bo'Ao Bio-Pharmaceutical)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant hormoneBiologics > Biosimilar
Mechanisms of ActionInsulin receptor agonists
TargetsInsulin receptor
Therapy Area/IndicationsDiabetes Mellitus, Type 2Diabetes Mellitus
Global Approved IndicationsDiabetes Mellitus
Approved Indications in ChinaDiabetes Mellitus
Original Approved Country/TerritoryMainland China
Original Approved Date2023/12/05
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesLiaoning Bo'Ao Bio-Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesLiaoning Bo'Ao Bio-Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsDiabetes Mellitus
Inactive IndicationsDiabetes Mellitus, Type 2

Other Information

ATC CodeN/A
Related LinksN/A